Dementia is very common in the late stage of patient with Parkinson’s disease (PD). We aim to explore its underlying pathogenesis and identify candidate biomarkers using untargeted metabolomics analysis. Consecutive PD patients and healthy controls were recruited. Clinical data were assessed and patients were categorized into Parkinson’s disease without dementia (PDND) and Parkinson’s disease dementia (PDD). Fast plasma samples were obtained and untargeted liquid chromatography-mass spectrometry-based metabolomics analysis was performed. Based on the identified differentially-expressed metabolites from the metabolomics analysis, multivariate linear regression analyses and receiver operating characteristic (ROC) curves were further employed. According to the clinical data, the mean ages of PDND and PDD patients were significantly higher than those of healthy controls. The incidence of hypercholesterolemia was decreased in PDD patients. PDD patients also had lower levels of triglyceride, low-density lipoprotein cholesterol, and apolipoprotein B. There were 24 and 57 differentially expressed metabolites in PDD patients when compared with the healthy controls and PDND patients from the metabolomics analysis. Eleven lipid metabolites were simultaneously decreased between these two groups, and can be further subcategorized into fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, and prenol lipids. The plasma levels of the eleven metabolites were positively correlated with MMSE score and can be candidate biomarkers for PDD patients with areas under the curve ranging from 0.724 to 0.806 based on the ROC curves. Plasma lipoproteins are significantly lower in PDD patients. A panel of eleven lipid metabolites were also decreased and can be candidate biomarkers for the diagnosis of PDD patients. Lipid metabolic dysregulation is involved in the pathogenesis of Parkinson’s disease dementia.

痴呆症在帕金森病 (PD) 患者的晚期非常常见。我们的目标是探索其潜在的发病机制，并使用非靶向代谢组学分析确定候选生物标志物。招募了连续的 PD 患者和健康对照。评估临床数据并将患者分类为无痴呆的帕金森病 (PDND) 和帕金森病痴呆 (PDD)。快速获取血浆样品并进行非靶向液相色谱-质谱代谢组学分析。基于从代谢组学分析中鉴定出的差异表达代谢物，进一步采用多元线性回归分析和受试者工作特征 (ROC) 曲线。根据临床资料，PDND和PDD患者的平均年龄显着高于健康对照组。PDD患者高胆固醇血症的发生率降低。PDD 患者的甘油三酯、低密度脂蛋白胆固醇和载脂蛋白 B 的水平也较低。与健康对照和代谢组学分析的 PDND 患者相比，PDD 患者有 24 和 57 种差异表达的代谢物。11 种脂质代谢物在这两组之间同时减少，可以进一步细分为脂肪酰基、甘油脂、甘油磷脂、鞘脂和异戊二烯脂。11 种代谢物的血浆水平与 MMSE 评分呈正相关，可以作为 PDD 患者的候选生物标志物，曲线下面积从 0.724 到 0。806 基于 ROC 曲线。PDD患者的血浆脂蛋白显着降低。一组 11 种脂质代谢物也减少了，可以作为诊断 PDD 患者的候选生物标志物。脂质代谢失调参与帕金森病痴呆的发病机制。